{
 "ticker": "IBBQ",
 "name": "Invesco Nasdaq Biotechnology ETF",
 "issuer": "Invesco",
 "desk": "themes",
 "url": "https://etfiq.com/funds/IBBQ",
 "html": "https://etfiq.com/funds/IBBQ",
 "markdown": "https://etfiq.com/funds/IBBQ.md",
 "as_of": "2026-09-11",
 "verdict": "IBBQ holds 249 stocks, and 62% of its weight is outside the S&P 500.",
 "key_facts": [
  {
   "key": "already_in_the_s_p_500",
   "label": "Already in the S&P 500",
   "value": "38.1%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBBQ, already in the S&P 500: 38.1%, as of Sep 11, 2026."
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBBQ, active share vs the S&P 500: 99.0%, as of Sep 11, 2026."
  },
  {
   "key": "top_ten_holdings",
   "label": "Top ten holdings",
   "value": "44.4%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBBQ, top ten holdings: 44.4%, as of Sep 11, 2026."
  },
  {
   "key": "total_return_1_year",
   "label": "Total return, 1 year",
   "value": "+43.5%",
   "source": null,
   "as_of": "2026-09-11",
   "sentence": "IBBQ, total return, 1 year: +43.5%, as of Sep 11, 2026."
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$67m",
   "source": "SEC filing, whole fund, as filed for May 31, 2026",
   "as_of": "2026-09-11",
   "sentence": "IBBQ, net assets: $67m (SEC filing, whole fund, as filed for May 31, 2026)."
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.19%",
   "source": "485BPOS XBRL, Dec 18, 2025",
   "as_of": "2026-09-11",
   "sentence": "IBBQ, expense ratio: 0.19% (485BPOS XBRL, Dec 18, 2025)."
  }
 ],
 "fields": [
  {
   "key": "theme",
   "label": "Theme",
   "value": "Biotech and genomics",
   "source": "ETFIQ, editorial"
  },
  {
   "key": "launched",
   "label": "Launched",
   "value": "Jun 11, 2021",
   "source": null
  },
  {
   "key": "already_in_the_s_p_500_by_weight",
   "label": "Already in the S&P 500, by weight",
   "value": "38.1%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_s_p_500",
   "label": "Active share vs the S&P 500",
   "value": "99.0%",
   "source": "ETFIQ"
  },
  {
   "key": "already_in_the_nasdaq_100_by_weight",
   "label": "Already in the Nasdaq-100, by weight",
   "value": "33.5%",
   "source": "ETFIQ"
  },
  {
   "key": "active_share_vs_the_nasdaq_100",
   "label": "Active share vs the Nasdaq-100",
   "value": "97.4%",
   "source": "ETFIQ"
  },
  {
   "key": "top_ten_holdings_weight",
   "label": "Top ten holdings weight",
   "value": "44.4%",
   "source": null
  },
  {
   "key": "holdings",
   "label": "Holdings",
   "value": "249",
   "source": null
  },
  {
   "key": "holdings_as_of",
   "label": "Holdings as of",
   "value": "Sep 10, 2026",
   "source": "the issuer\u2019s daily file"
  },
  {
   "key": "top_holdings",
   "label": "Top holdings",
   "value": "Vertex Pharmaceuticals Inc 8.1%, Amgen Inc 8.1%, Gilead Sciences Inc 7.6%, Regeneron Pharmaceuticals Inc 5.5%, Moderna Inc 3.7%, Revolution Medicines Inc 2.9%, Alnylam Pharmaceuticals Inc 2.2%, Biogen Inc 2.1%, Illumina Inc 2.1%, Roivant Sciences Ltd 2.0%",
   "source": null
  },
  {
   "key": "net_assets",
   "label": "Net assets",
   "value": "$67m",
   "source": "SEC filing, whole fund, as filed for May 31, 2026"
  },
  {
   "key": "below_its_all_time_high",
   "label": "Below its all-time high",
   "value": "\u22126.4%",
   "source": "ETFIQ"
  },
  {
   "key": "expense_ratio",
   "label": "Expense ratio",
   "value": "0.19%",
   "source": "485BPOS XBRL, Dec 18, 2025"
  },
  {
   "key": "fee_for_the_part_that_differs_from_the_s_p_500_active_expense_ratio",
   "label": "Fee for the part that differs from the S&P 500, active expense ratio",
   "value": "0.19%",
   "source": "ETFIQ"
  },
  {
   "key": "closest_funds_by_holdings_overlap",
   "label": "Closest funds by holdings overlap",
   "value": "BBH 53%, PBE 38%, BBP 35%, BMED 34%, FBT 33%",
   "source": null
  }
 ],
 "periods": [
  {
   "window": "3 months",
   "Total return": "+16.7%",
   "S&P 500": "+3.3%",
   "Gap to S&P 500": "+13.4 pts",
   "Gap to Nasdaq-100": "+17.5 pts"
  },
  {
   "window": "6 months",
   "Total return": "+21.4%",
   "S&P 500": "+16.0%",
   "Gap to S&P 500": "+5.4 pts",
   "Gap to Nasdaq-100": "+0.7 pts"
  },
  {
   "window": "1 year",
   "Total return": "+43.5%",
   "S&P 500": "+17.5%",
   "Gap to S&P 500": "+26.0 pts",
   "Gap to Nasdaq-100": "+20.5 pts"
  },
  {
   "window": "3 years",
   "Total return": "+72.6%",
   "S&P 500": "+77.9%",
   "Gap to S&P 500": "\u22125.3 pts",
   "Gap to Nasdaq-100": "\u221222.5 pts"
  },
  {
   "window": "Since launch",
   "Total return": "+41.1%",
   "S&P 500": "+93.4%",
   "Gap to S&P 500": "\u221252.3 pts",
   "Gap to Nasdaq-100": "\u221275.0 pts"
  }
 ],
 "questions": [
  {
   "q": "How much of IBBQ is in S&P 500 companies?",
   "a": "By its holdings published by its issuer for Sep 10, 2026, 38% of IBBQ by weight is stocks the S&P 500 already holds. Its active share against the index is 99%, so that share is the part doing something different."
  },
  {
   "q": "What does IBBQ hold?",
   "a": "249 positions as published by its issuer for Sep 10, 2026, with the top ten at 44% of the fund. The largest are Vertex Pharmaceuticals Inc at 8.1%, Amgen Inc at 8.1%, Gilead Sciences Inc at 7.6%."
  },
  {
   "q": "Has IBBQ beaten the S&P 500?",
   "a": "Over the year to Sep 11, 2026 IBBQ returned +43.5% with distributions reinvested, against +17.5% for the S&P 500, so it finished ahead of the index by 26.0 points."
  },
  {
   "q": "What does IBBQ cost?",
   "a": "The prospectus expense ratio is 0.19% a year. Because 99% of the fund differs from the S&P 500, the fee on that differing part works out at 0.19%."
  }
 ],
 "generated": "2026-09-13",
 "license": "Free to use with attribution. ETFIQ (etfiq.com)."
}